Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.83 | N/A | +6.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.83 | N/A | +6.84% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They noted positive trends in product demand, although no specific guidance was provided.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to innovation and pipeline development.
Amgen's earnings report showed a solid EPS beat, which contributed to a slight increase in the stock price. The positive surprise in EPS indicates better-than-expected profitability, reflecting strong performance in its key therapeutic areas. However, the lack of revenue data and guidance leaves some uncertainty for investors looking for future direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 23, 2018